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CObjective: This study aimed to examine factors that influenced the
rising Coxibs expenditure. Methods: Retrospective utilization data
ere retrieved from hospital’s database. Changes in Coxibs expendi-
ure in 2007 and 2009, calculated by using the Laspeyres index, were
ttributed to two factors: cost per patient (P) and number of patients (Q)
er year. By measuring quantity as defined daily dose, changes in
comprised two subfactors: cost per day (p) and days of therapy per
atient (q); p was weighted average cost of Coxibs per day, and q was
eighted average days of therapy of new and current patients. Further-
ore, the pattern of concomitant drugs, proton pump inhibitors, was
nalyzed. Results: Expenditure on Coxibs rose from57.7 to 69.4million
aht from 2007 to 2009. With Laspeyres index, total index of 1.20 was a
esult of three main factors. The highest impact was from change in
ost per day (p index at 1.17), which was a result of a slight increase in O
e no
t of H
al So
doi:10.1016/j.vhri.2012.03.003rug cost, mainly weighted by product mix, which tended to switch
rug from low to high cost. Another positive impact was the number of
oxibs patients (Q index at 1.04). Finally, the negative impact was from
ays of therapy per patient (q index  0.98). Although days of therapy
er patient for both new and current patients were decreased, patient
ix of more current patients slowed the decrease down. In addition,
he percentage of proton pump inhibitors coprescription also rose from
0.8% in 2007 to 32.3% in 2009. Conclusion: Switching drug from low to
igh cost is a major factor that impacted the rising of expenditure on
oxibs.
eywords: Coxibs, cyclooxygenase (COX)-2-selective inhibitors, drug
xpenditure, Laspeyres index
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Nonsteroidal anti-inflammatorydrugs (NSAIDs) areusedextensively
in health services to relieve pain and health conditions with an in-
flammatory component. NSAIDs, however, can induce adverse
events, especially gastrointestinal (GI) disturbance. A gastroprotec-
tive agent can be coprescribed to reduce the risk of aGI event. During
the past decade, a new formofNSAIDs called cyclooxygenase (COX)-
2-selective inhibitors or Coxibs has been developed. This new drug
group can inhibit the cyclooxygenase 2 enzyme that is responsible
for the inflammatory effect without inhibiting the cyclooxygenase 1
enzyme that helps protect themucosa lining of theGI tract [1]. There
was also, however, growing evidence to assume that there are in-
creased risks of cardiovascular events instead in patients using
Coxibs [2].
Since 1999, with the introduction of Coxibs in Thailand, the
total expenditure on NSAIDs has been rising dramatically. In the
first 2 years of their launch, expenditures on Coxibs increased
from 6.5% in the first quarter of 2000 to 52.1% of NSAIDs’ expendi-
ture in the last quarter of 2002 in 18 provincial hospitals in Thai-
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Published by Elsevier Inc.land. The use of Coxibs rather thanNSAIDswould raise the annual
expenditure per person by as much as 11 times [3].
At Ramathibodi Hospital, a 900-bed government teaching facil-
ity in Bangkok, expenditure on Coxibs increased 20.4% from 2007
to 2009 (data from Ramathibodi Hospital’s database from October
1, 2005, to September 30, 2009) despite the implementation of a
drug utilization evaluation program in 2007 for five Coxibs
(meloxicam, celecoxib, etoricoxib, lumiracoxib, and nabumetone).
Only patients with one of the following four criteria are able to get
the drugs: 1) aged more than 70 years without any cardiovascular
renal disease, 2) allergic to any of conventional NSAIDs, 3) had
significant peptic ulcer/bleeding/perforation in the past, or 4) had
GI complication even after taking conventional NSAIDs with gas-
troprotective agents [4].
BecauseCoxibs’majorbenefitoverconventionalNSAIDs isbetterGI
tract protection [1,5], it is expected that the concomitantuseof aproton
pump inhibitor (PPI), a gastroprotective agent, would be reduced [6].
Dataatthehospital,however,showedthatnotonlyCoxibs’expenditure
but also PPIs’ was still moving up (data from Ramathibodi Hospital da-
tabase fromOctober 1, 2005, to September 30, 2009).
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with Laspeyres index [7,8] was applied and computed as follows:
Laspeyres index (total expenditure where one factor changed
to a selected period while holding other factors to its
previous period) ⁄ (total expenditure in previous period)
Index greater than 1 indicates that the considered factor has a
positive impact on total expenditure, while index less than 1
means a negative impact.
This study aimed to describe the trend of Coxibs and PPI utili-
zation from fiscal year 2007 to 2009 and to determine factors at-
tributed to its rising expenditure at a teaching hospital and explain
the change by using the Laspeyres index.
Methods
Data of this descriptive study were prescription records of oral
drugs under the Anatomical and Therapeutic Classification code
“M01A” (Anti-inflammatory and antirheumatic products, non-
steroids) and “A02BC” (PPIs), used for both outpatients and inpa-
tients from October 1, 2005, through September 30, 2009 (Thai fis-
cal year, FY 2006–2009). Each data record comprised patient’s
hospital number, health insurance schemes (Universal Coverage
[UC], Social Security Scheme [SSS], Civil Servants Medical Benefit
Scheme [CSMBS], or self-pay) of each visit/admission, prescribing
date, drug’s code and name, prescribed quantity (e.g., tablet and
capsule), and unit selling price. Data were cleaned for any dupli-
cation. Dispensed drug quantitywas calculated as days of therapy,
based on defined daily dose (DDD):
Days of therapy (prescribed quantity)
 (strength in milligram) ⁄ DDD
where DDD is the assumed average maintenance dose per day for
a drug used for its main indication in adults [9]; see DDD of each
drug in Table 1.
For data analysis, Coxibs and PPI utilization rateswere compared
between the two time periods, FY 2007 (period t  1) and FY 2009
(period t). The previous 1-year data of each time period were also
included to identify whether the patient was new or current (e.g.,
new patients in 2007 were the ones without Coxibs prescription in
2006). Pattern of PPIs use as concomitant drug, determined as per-
centage of days of therapy, and prescriptions of Coxibs utilization in
each time period were compared between the two time periods.
Annual Coxibs expenditure of the two time periods was calcu-
lated as summation of (prescribed quantity)  (unit price), by Mi-
crosoft Access 2007 and Excel 2007 for each health scheme.
Table 1 – Oral Coxibs available at Ramathibodi Hospital: m
therapy) between 2007 and 2009.
ATC code DDD
(mg)
Generic name (mg) % Market
share
2007 2009
Curr
M01AC06 15 Meloxicam (7.5, 15) 12.1 8.7
M01AH01 200 Celecoxib (200, 400) 34.3 40.5
M01AH05 60 Etoricoxib (60, 90, 120) 31.1 50.7
M01AH06 100 Lumiracoxib (100, 400) 22.1 0.0
M01AX01 1000 Nabumetone (500) 0.4 0.1
ATC, Anatomical and Therapeutic Classification; DDD, defined dailyChange in annual expenditure between the two time periods waspresented by total index. Total index and its contributing factors
were determined by using the Laspeyres index with the following
mathematic model:
Total index (P index) (Q index) (p index q index)
 (Q index)
where P is the Coxib’s cost per patient per year (Thai baht),Q is the
number of patients per year, p is the weighted average cost of
Coxibs per day, and q is the weighted average number of days of
therapy of new and current patients.
The weighted average cost of Coxibs per day or p was a sum-
mation of Coxibs’ cost per DDD multiplied by their product mix,
while product mix was a ratio of days of therapy of Coxibs pre-
scribed to patient.
pn  1 to 5 (cost ⁄ DDD)n (% days of therapy)n
where n is each Coxibs.
Switching froma lower- to a higher-cost drug thenwouldmake
the index positive, and vice versa.
Weighted average days of therapy of new and current patients
or qwere a summation of days of therapy per patientmultiplied by
their patient mix.
qn  1 to 2 (days of therapy)n % patient mixn
where n is new and current patients, and patientmixwas a ratio of
new and current patients.
Results
Trend of Coxibs and PPI utilization
During the study period, lumiracoxib was removed from hospital
list in FY year 2009. Table 2 shows patients’ demographic charac-
teristics in each time period. The total number of patients with at
least one Coxibs prescriptionwas 36,232 and 37,837 in 2007 and 2009
(4.43% increase), respectively, with the mean age of 54.8  14.5 and
55.1  14.5 years, respectively. One-fourth were males in both time
periods.Overall, 66.1%and52.3% in 2007 and2009 did not get Coxibs
in the previous year. Most patients were under CSMBS and self-
pay, which pay by fee-for-services, 96.6% and 97.1% in 2007 and
2009, while the other two insurance schemes pay by capitation.
Coxibs expenditure increased 20.4% from 57.7million baht in 2007
to 69.4million baht in 2009; per capita, it was a 15.3% increase from
1592 baht in 2007 to 1835 baht in 2009.
Table 2 also shows that the concomitant use of PPI increased
from30.8% to 32.3% of total days of therapy, or from 25.2% to 25.8%
t share, product mix, and patient mix (as ratio of days of
% Product mix
2007 2009
atients New patients Current patients New patients
5.1 5.5 3.2
15.0 27.3 13.2
14.2 32.5 18.2
14.0 0.0 0.0
0.1 0.1 0.0
% 48.5% 65.4% 34.6%arke
ent p
7.1
19.3
16.9
7.9
0.3
51.5of total Coxibs prescriptions in 2007 and 2009, respectively.
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and 2009 and patientmix during the two time periods. Overall, the
percentage of Coxibs prescribed to new patients decreased from
48.5% to 34.6%. In 2007, celecoxib had the highest share (15.0% to
new and 19.3% to current patients), followed by etoricoxib, lumira-
coxib, meloxicam, and nabumetone. In 2009, etoricoxib moved up
to the highest share (18.2% to new and 32.5% to current patients),
followed by celecoxib, meloxicam, and nabumetone, while lu-
miracoxib was unlisted from the hospital formulary.
Factors affecting Coxibs expenditure
Change in Coxibs expenditure from 57.7 million baht in 2007 to
69.4 million baht in 2009 resulted in a total index of 1.20 (Table 3).
The total index comprised two main factors: quantity or number
of Coxibs patients (Q index) and price or cost per patient (P index),
which equaled 1.04  1.15. For more details, cost per patient, or P
index, was a result of two subfactors: cost per day multiplied by
days of therapy per patient (1.15  1.17  0.98). Cost per day, or p,
was a weighted average of five drug costs by their product mix,
measured as percentage of days of therapy of each drug. Change in
all five drugs costs in 2009, while holding other factors constant to
2007, impacted the p index by 1.04. While holding all factors con-
tant, except productmix or percentage of prescribed days of ther-
py changed to 2009, impacted the p index at 1.12.
Table 2 – Patients’ demographic and Coxibs utilization
at Ramathibodi Hospital, 2007 and 2009.
2007 2009
Total population 36,232 37,837
Age (y), mean  SD 54.8  14.5 55.1  14.5
% Males 24.6 25.7
% Health scheme
UC 2.0 1.8
SSS 1.4 1.1
CSMBS 36.7 53.8
Self-pay 59.9 43.3
% New patients 66.1 52.3
Percentage PPIs as concomitant drugs
By prescriptions 25.2 25.8
By days of therapy 30.8 32.3
CSMBS, Civil Servants Medical Benefit Scheme; PPIs, proton pump
inhibitors; SSS, Social Security Scheme; UC, Universal Coverage.
Table 3 – Total Coxibs expenditure and by health scheme a
2007 and 2009.
Total UC
2007 2009 Index 2007 2009 Inde
Total Coxibs expenditure
(million baht)
57.68 69.43 1.20 0.66 0.54 0.82
1. Number of patients (Q) 36,232 37,837 1.04 721 674 0.93
2. Cost/patient (P) 1,591.9 1,835.1 1.15 916.8 799.9 0.87
2.1. Cost/day (p) 26.3 30.9 1.17 24.9 29.6 1.19
Cost per DDD 1.04 1.03
% Product mix 1.12 1.15
2.2. Days of therapy/
patient (q)
60.5 59.4 0.98 36.9 27.1 0.73
Days of therapy/patient 0.89 0.70
% Patient mix 1.11 1.03
Note. % Product mix is ratio of days of therapy of each Coxib; % Patie
CSMBS, Civil Servants Medical Benefit Scheme; DDD, defined daily dose; SWith the same concept, days of therapy per patient, or q, was a
weighted average of days of therapy per patient by percentage of
patient mix. Change in days of therapy per patient in 2009, while
holding other factors constant to 2007, would make the q index to
be 0.89, and 1.11 when the patient mix changed to 2009. Shifting
ratio from new patients (66.1% in 2007 to 52.3% in 2009) who were
prescribed with a lower number of days of therapy (44.5) to current
patients (91.8) would drive the q index to be more positive (Table 4).
By health insurance schemes, 26.9 million baht (46.7% of total
Coxibs expenditure) was prescribed to patients under CSMBS in
2007 and this increased to 44.7 million baht in 2009 (64.3% of total
Coxibs expenditure). For SSS patients, from 2007 to 2009, Coxibs
expenditure also rose from 0.4 (0.6%) to 0.5 (0.7%) million baht,
while for self-pay and UC patients, it decreased from 29.7 (51.5%)
to 23.8 (34.2%) and 0.7 (1.2%) and 0.5 (0.8%) million baht, respec-
tively (Table 3).
Total Coxibs expenditure indexes were 0.82, 1.36, 1.66, and 0.80
for patients under UC, SSS, CSMBS, and self-pay, respectively. Only
theQ index for CSMBSwas greater than 1, at 1.53, while for the other
schemes, it was less than 1. On the other hand, only the P index for
C was less than 1, at 0.87; for others, it was greater than 1.
Cost per day rose in all schemes (all p indexes were 1). Days of
herapy per patient (q index) in all schemes decreased, except for SSS
or which the q index was greater than 1, at 1.44. Finally, indexes of
oth product and patient mix for all schemes were more than 1.
Discussion
The mathematic model in which each variable changes according
to a mathematical formula has been applied in the health field
since 1970s [10]. In Thailand, Limwattananon et al. [11] used the
model to analyze and forecast drug expenditure for outpatients in
mathibodi Hospital, its factors and index—fiscal years
SSS CSMBS Self-pay
07 2009 Index 2007 2009 Index 2007 2009 Index
.35 0.48 1.36 26.93 44.66 1.66 29.73 23.76 0.80
428 0.85 13,306 20,340 1.53 21,702 16,395 0.76
.4 1119.2 1.60 2,024.3 2,195.7 1.08 1,369.9 1,448.9 1.06
.5 29.3 1.11 26.7 31.0 1.16 26.0 30.9 1.19
1.02 1.03 1.05
1.08 1.12 1.13
.4 38.2 1.44 75.9 70.9 0.93 52.7 47.0 0.89
1.21 0.85 0.85
1.07 1.12 1.04
ix is the ratio of current and new patients.
Table 4 – Number of days of Coxibs therapy per patient
and patient mix at Ramathibodi Hospital fiscal years
2007 and 2009.
2007 2009
Current
patients
New
patients
Current
patients
New
patients
DDD/patient 91.8 44.5 81.3 39.4
% Patient mix 33.9 66.1 47.7 52.3
DDD, defined daily dose.t Ra
x 20
0
503
699
26
26
nt m
SS, Social Security Scheme; UC, Universal Coverage.
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2003, and December 31, 2007. Similar to this study, the model ex-
plained two components of total expenditure, unit price and uti-
lization quantity, where utilization quantity was composed of
three factors: number of drug recipients, propensity to use, and
intensity of use. In Asia, the concept of applying a mathematic
model in health care industry has not been much researched. Re-
cently, Zhang et al. [12] applied the structural decomposition anal-
ysis model combining it with the “refined Laspeyres” method to
analyze the relative importance of the driving factors in the dy-
namic changes of the relationships between economic growth and
environmental pressure in Gansu Province from 1990 to 2005. And
Chen et al. [13] investigated the use and trend of drugs for the
digestive system in Hangzhou area from 2005 to 2007 by using the
Laspeyres index.
In this study, the 20.4% increase in Coxibs expenditure from 2007
to2009wasa result of threemain factors. First, Coxibsutilizationwas
switched from lower- to higher-cost drugs. Second was the increase
in the totalnumberofCSMBSpatientswhowereprescribedwith long
days of therapy and accounted for themajority of all patients. Third,
the mix of patient moved to more current ones who tended to be
prescribed with more days of therapy than new patients.
First, Coxibs utilization was switched from low-cost drugs (lu-
miracoxib andmeloxicam) to high-cost drugs (celecoxib and etori-
coxibs). The weighted average daily cost of Coxibs per patient (p
index) was more than 1 in every health scheme (Table 3), affected
mainly by the change in the percentage of market share. From
Table 1, etoricoxib, the second rank at 31.1% (with 30.1 baht per
DDD) in 2007, was moved to the first rank at 50.7% (with 32.0 baht
per DDD) in 2009, while the first rank in 2007, celecoxib 34.3% (with
28.7 baht per DDD), also gained themarket, but at a slower rate, to
40.5% (with 29.2 baht per DDD) in 2009. Most of the gain in the
market share of the two drugs was from the lower-cost drug, lu-
miracoxib (15.1 baht per DDD). Meloxicam and nabumetone, the
fourth and fifth ranks in 2007, had a combined share of 12.5% and
8.8% in 2007 and 2009, also indicating a shift to a higher-cost drug.
Second, the total number of patients increased, especially
CSMBS patients who got long days of Coxibs therapy. From 2007 to
2009, only patients under CSMBS were increased (Q index of 1.53).
A shift to CSMBS was a result of the change in system factor of
direct reimbursement, the major health care reform in Thailand
by the Ministry of Finance in 2006 [14]. By this policy, CSMBS pa-
tients were relieved of the burden of cash advancement and en-
couraged less self-pay. Furthermore, the majority patients, under
CSMBS and self-pay, were prescribed with more DDD than were
UC and SSS patients. Although the cost per day for each patient
was notmuch different, 24.9 to 26.7 in 2007 and 29.3 to 31.0 in 2009,
days of therapy per patient under CSMBS and self-pay (47.0–75.9
DDD)were 2 to 3 times over UC and SSS (26.4–38.2 DDD). A study of
Limwattananon et al. [3] revealed that in 2009, 91% of Coxibs were
prescribed to CSMBS patients, with 12% to 16% growth per year
from 2007. Table 3 also reveals that only patients under SSS were
prescribed with longer days of therapy (q index more than 1).
Third, current patients in 2009 gainedmore market share than
did new patients (65.4:34.6) when compared with the ratio in 2007
(51.5:48.5). In addition, current patients were prescribed with
twice the number of days of therapy (81.3) when compared with
new patients (39.4) in 2009. This may indicate more chronic use of
Coxibs in current patients.
Although Coxibs were claimed to reduce the prescription of
gastroprotective agents, which was assumed to be one of their
major benefits [1,5], our study presented that the number of PPIs
coprescription was also increased. Similar results were found in
2001 by Formoso et al [6], who also found a higher coprescription
rate in chronic Coxibs users than in chronic NSAIDs users.
This study also recognized some limitations. First was the ac-
curacy of health scheme recording, because it was an electronicdata fromadrug dispensingmodule. Patients under any insurance
but who paid cash would be defined as self-pay. Second, clinical
outcomeswere not included in the study. And thirdwas the lack of
a prescribed daily dose; therefore, DDD was used instead.
Conclusions
Coxibs expenditure of a Thai teaching hospital increased 20.4%
from 2007 to 2009. Our study found that 98% to 99% of patients
were under CSMBS and self-pay, both of which had a higher utili-
zation rate than the ones under UC and SSS. A mathematic model
was then applied and explained three factors that affected the
total index at 1.20. The highest impactwas from the change in cost
per day (p index at 1.17), which was a result of a slight increase in
drug cost, weighted by product mix, a switch from a lower- to a
higher-cost drug. Another positive impact was the number of
Coxibs patients (Q index) at 1.04, especially among CSMBS pa-
tients. Finally, the negative impact was from DDD per patient.
Although days of therapy per patient for both new and current
were decreased, the patient mix of more current patients slows
the decrease down with the q index at 0.98. In addition, the per-
centage of PPIs coprescription also rose from 30.8% in 2007 to
32.3% in 2009. The findings can help the administration to under-
stand the causes of rising drug expenditure and provide the ap-
propriate policy to control its utilization; however, clinical out-
come should be included for further analysis.
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